Adaptive Biotechnologies targets 30%+ clonoSEQ test volume growth in 2026 while expanding margins and data partnerships

Adaptive Biotechnologies Corporation (ADPT) Q4 2025 Management View Chad Robins, Co-Founder, CEO & Chairman, highlighted ...
StockStory.org on MSN

LH Q4 deep dive: Specialty testing and hospital partnerships offset volume challenges

Healthcare diagnostics company Labcorp Holdings (NYSE:LH) in Q4 CY2025, but sales rose 5.6% year on year to $3.52 billion. On the other hand, the company’s outlook for the full year was close to ...
Seeking Alpha

GeneDx: Strong Testing Volume And An Invaluable Genomic Database

GeneDx leverages a vast rare disease database and advanced genomic testing, offering superior insights over traditional panel testing. The company achieved a significant turnaround, becoming cash flow ...
Yahoo Finance

Myriad Genetics (MYGN) Test Volume Rises Amid Margin Woe

Myriad Genetics’ MYGN strong product portfolio raises our optimism. The company’s impressive transformation and growth strategy also encourages us. Yet, emerging competitors and rising expenses ...
Insider Monkey

Accelerated Testing Volume Lifted CareDx (CDNA) in Q3

Baron Funds, an investment management company, released its “Baron Discovery Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here. In the third quarter, the fund ...